European Journal of Inflammation (Jul 2021)

Performance of CURB-65, PSI, and APACHE-II for predicting COVID-19 pneumonia severity and mortality

  • Junnian Chen,
  • Bang Liu,
  • Houwei Du,
  • Hailong Lin,
  • Cunrong Chen,
  • Shanshan Rao,
  • Ranjie Yu,
  • Jingjing Wang,
  • Zhiqiang Xue,
  • Yixian Zhang,
  • Yanghuang Xie

DOI
https://doi.org/10.1177/20587392211027083
Journal volume & issue
Vol. 19

Abstract

Read online

No prognostic tools for the prediction of COVID-19 pneumonia severity and mortality are available. We explored whether CURB-65, PSI, and APACHE-II could predict COVID-19 pneumonia severity and mortality. We included 167 patients with confirmed COVID-19 pneumonia in this retrospective study. The severity and 30-day mortality of COVID-19 pneumonia were predicted using PSI, CURB-65, and APACHE-II scales. Kappa test was performed to compare the consistency of the three scales. There was a significant difference in the distribution of the scores of the three scales ( P < 0.001). Patients with PSI class ⩽III, CURB-65 ⩽1, and APACHE-II-I all survived. The ROC analysis showed the areas under the curve of the PSI, CURB-65, and APACHE-II scales were 0.83 (95% CI, 0.74–0.93), 0.80 (95% CI, 0.69–0.90), and 0.83 (95% CI, 0.75–0.92), respectively. Our findings suggest that PSI and CURB-65 might be useful to predict the severity and mortality of COVID-19 pneumonia.